Modified vaccinia Ankara - Bavarian Nordic
Alternative Names: IMVAMUNE; IMVAMUNE® liquid-frozen; IMVAMUNE® freeze-dried; IMVANEX; JYNNEOS; Monkeypox vaccine - Bavarian Nordic; MVA-BN; MVA-BN® Smallpox; MVA-BN® freeze-dried; MVA-BN® liquid-frozen; MVA-BN® smallpox vaccine; Smallpox and monkeypox vaccine - Bavarian NordicLatest Information Update: 30 Sep 2024
At a glance
- Originator Bavarian Nordic
- Developer Bavarian Nordic; Centers for Disease Control and Prevention; National Institute of Allergy and Infectious Diseases; National Institutes of Health (USA)
- Class Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Monkeypox; Smallpox; Vaccinia virus infections
Most Recent Events
- 25 Sep 2024 The US Biomedical Advanced Research and Development Authority (BARDA) exercises the contract of additional smallpox vaccine from Bavarian Nordic
- 19 Sep 2024 European Commission approves a type II variation for IMVANEX® (MVA-BN) Smallpox and Monkeypox vaccine to include adolescents 12 to 17 years of age in European Union
- 19 Sep 2024 Immunogenicity and adverse events data from a phase II trial in Monkeypox released by Bavarian Nordic